Company: PTHS
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001753926-25-001561
Chunk: 9

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-29
Form: 424B3
Chunk 9
---
 an approximately 17 million people of all ages in the United States.

<div align='center'>5</div>

On July 10, 2025, we announced the launch and commercialization of ZELSUVMI and have built our sales, marketing and commercial team to launch ZELSUVMI. The Company expects pediatricians, pediatric dermatologists, dermatologists and infectious disease specialists will be the target prescribers.

On the Merger Closing Date, we consummated the previously announced Merger contemplated by Merger Agreement. Pursuant to the Merger Agreement, (i) Merger Sub merged with and into LNHC, with LNHC as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of the Company and (ii) Channel’s name was changed from Channel Therapeutics Corporation to Pelthos Therapeutics Inc.

Channel was incorporated in Delaware on March 19, 2021. On November 18, 2024, Chromocell Therapeutics Corporation, a Delaware corporation, merged with and into its wholly-owned subsidiary, Channel, pursuant to an agreement and plan of merger, dated as of November 18, 2024, for the purposes of reincorporation Channel in Nevada.

Channel was a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus was to selectively target the sodium ion-channel known as “NaV1.7”, which has been genetically validated as a pain receptor in human physiology. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”). Channel’s goal is to develop a novel and proprietary class of NaV blockers that target the body’s peripheral nervous system. Prior to the consummation of the Merger, Channel’s stock was traded on The NYSE American under the ticker symbol “CHRO”.

All information disclosed in this Registration Statement prior to the Merger Closing Date relates to Channel, and all information disclosed in this registration statement for periods after the Merger Closing Date relates to Pelthos.

Our principal executive offices are located at 4020 Stirrup Creek Drive, Suite 110, Durham, NC, and our telephone number is (919) 908-2400. Our website is https://pelthos.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this information statement, and you